Drug updated on 4/18/2024
| Dosage Form | Injection (intravenous; 0.5mmol/mL) |
| Drug Class | Gadolinium-based contrast imaging agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in adult and pediatric patients aged 2 years and older for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in: the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).
Summary
- Gadopiclenol (Elucirem) is appropriate for use with magnetic resonance imaging to detect and visualize lesions with abnormal vascularity in the central nervous system and body for both adult and pediatric patients aged 2 years and older.
- The efficacy of Elucirem extends across a continuum, displaying favorable results at higher doses. This highlights its potential to provide superior diagnostic images while utilizing smaller quantities of the agent compared to other gadolinium-based contrast agents.
- Although specific data based on age or disease type is not provided, Elucirem's broad indication suggests its wide applicability across different patient populations. More detailed insights into how specific subgroups respond to this agent are anticipated from future research.
- In terms of the safety profile, Elucirem appears acceptable and aligns with that of other gadolinium-based contrast agents. However, high rates of retention within the liver are mentioned as points requiring further investigation to fully understand their long-term implications.
- Serious adverse effects, such as severe kidney injury, were evaluated, with findings suggesting that Elucirem does not significantly differ from other similar agents in these areas. Organ-based contrast retention is a notable concern that distinguishes this agent from others but has not been directly linked to adverse clinical outcomes within the reviewed material.
- The reviewed study portrays Elucirem as maintaining a favorable safety profile, an important factor when comparing it against other gadolinium-based agents used for MRI procedures.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Elucirem (gadopiclenol) Prescribing Information. | 2022 | Guerbet LLC, Princeton, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Review of the efficacy and safety of gadopiclenol: A newly emerging gadolinium-based contrast agent. | 2023 | Cureus |